Advocates want Congress to ban DTC

Share this article:
Advocacy groups led by Commercial Alert, National Women's Health Network, and Physicians for a National Health Program are seeking support for legislation to ban DTC ads.

The draft legislation, which has not yet attracted any sponsors, claims that DTC does not promote public health but instead increases both drug costs and unnecessary prescriptions.

The bill would prohibit all DTC ads, including reminder and help-seeking ads directing people to Web sites intended to promote the sale of particular drugs.

An exception would be created for print ads that present only the names and prices of prescription drugs or inform consumers that certain drugs are available at certain locations.

If those provisions were found to be unconstitutional, the bill's fallback position is that:
(1) DTC drug ads must include additional warnings appropriate to the drug, informing consumers the drug was approved based on testing that included fewer than typically 3,000 people and may be dangerous in ways that limited research has not revealed, and the FDA does not certify that the drug is more effective, safer, or cheaper than others in its class; (2) DTC drug ads are not tax deductible; and (3) Drug companies are subject to a 3% windfall profits tax that is dedicated to a fund controlled by the National Institutes of Health for conducting studies on comparative benefits of drugs.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...